ISG12a mediates cell response to Newcastle disease viral infection
/in International Publications, Newcastle Disease Virus /von 2014-07-05 / Virology 2014 Aug;462-463:283-94Going viral with cancer immunotherapy
/in International Publications, Newcastle Disease Virus /von 2014-07-03 / Nat. Rev. Cancer 2014 Aug;14(8):559-67Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response
/in International Publications, Newcastle Disease Virus /von 2014-06-18 / J. Immunol. 2014 Jul;193(2):735-45Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer
/in International Publications, Newcastle Disease Virus /von 2014-06-11 / Front Oncol 2014;4:145γδ T cells in combination with Newcastle disease virus and dendritic cell therapy as a novel immunotherapeutic approach in treating of advanced lung cancer.
/in Dendritic Cells, International Publications, Newcastle Disease Virus, NSCLC, SCLC /von 2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3062)Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3051)Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer
/in International Publications, Newcastle Disease Virus, NSCLC /von 2014-05-12 / Virol. J. 2014 May;11:84Oncolytic viruses and their application to cancer immunotherapy
/in International Publications, Newcastle Disease Virus /von 2014-04-01 / Cancer Immunol Res 2014 Apr;2(4):295-300Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain
/in International Publications, Newcastle Disease Virus /von 2014-03-15 / Virus Res. 2014 Jun;185:10-22
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution